Tag Archives: Sagimet Biosciences

Madrigal and Sagimet Present MASH Data at EASL 2024

Two cardiometabolic-related news items have been observed: Madrigal Pharmaceuticals announced new Rezdiffra MASH data at the EASL 2024 conference (view press release); and Sagimet Biosciences presented Ph2b FASCINATE-2 denifanstat data at the EASL 2024 conference (view press release). Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Zealand Ph2a Dapiglutide Results; SixPeaks Launches as Obesity Startup with AZ Investment; Medtronic CY Q1 ’24 Earnings; Scholar Rock and Sagimet Investor Days; CLEAR Outcomes EU Approval

A series of cardiometabolic-related news items have been observed from Zealand Pharma, SixPeaks Bio, Medtronic, Scholar Rock, Sagimet Biosciences, and Esperion Therapeutics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Nanexa Receives CTA Approval for QM Liraglutide; Iconovo Files Patent for Inhaled GLP-1RAs; Sagimet, Galectin, and Dario Q1 ‘24 Earnings

A series of cardiometabolic-related news items have been observed from Nanexa, Iconovo, Sagimet, Galectin, and Dario. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.

Already a member? Log in here

FDA Approves Akebia’s Vadadustat; Inventiva and NeuroBo Q4 ’23 Earnings; Supersapiens to Relaunch in US; Sagimet MASH Development Updates

A series of cardiometabolic-related news items have been observed from Akebia Therapeutics, Inventiva, Supersapiens, Sagimet Biosciences, and NeuroBo Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here